Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 1/2 1

Status

Terminated 2Not yet recruiting 2Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 81Thoracic 46Other solid neoplasm 20Head & Neck 18Lymphoid 10Genitourinary 9Tumor-Agnostic 5Dermatologic 5Gynecologic 3Other hematologic neoplasm 2Breast 2Sarcoma 1

Conditions

Neoplasm Metastasis 3Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 55Specimen Handling 28Biopsy 28Magnetic Resonance Spectroscopy 26Paclitaxel 23Blood Specimen Collection 22Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8durvalumab 8Taxes 8Ipilimumab 8Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
tislelizumab × Tumor-Agnostic × 1 year × Clear all
NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
98 enrolled
Tumor-Agnostic

Neoplasms

NCT06540066 2026-03-16

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

BeOne Medicines

Phase 1 Terminated
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05935098 2026-03-13

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

BeOne Medicines

Phase 1 Terminated
99 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07348107 2026-01-16

ATARI-PDAC

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 1 Not yet recruiting
10 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡